Authors

Latest:

Dr. Parsons Discusses the Role of PARP 7 in Overall Survival of Patients With Ovarian Cancer

Lavanya Palavalli Parsons, MD, clinical fellow, The University of Texas Southwestern Medical Center, discusses the role of PARP 7 in overall survival of patients with ovarian cancer during the 2018 Society of Gynecologic Oncology Annual Meeting.

Lawrence B. Afrin, MD

Latest:

What I Have Learned Since Fellowship: Tips for Professional Success and Happiness

Tips for success from Lawrence B. Afrin, MD an associate professor of medicine in the Division of Hematology/Oncology at Medical University of South Carolina in Charleston.

Lawrence B Berk, MD, PhD

Latest:

A Comprehensive Review of Hemibody Irradiation for Patients with Bone Metastases

A comprehensive review was initiated on hemibody irradiation for patients with solid tumors with an emphasis on bone metastases to determine the efficacy and the toxicity of this treatment.

Lawrence D. Kaplan, MD

Latest:

Dr. Kaplan on Research With Bispecific Monoclonal Antibodies in Follicular Lymphoma

Lawrence D. Kaplan, MD, discusses research with bispecific monoclonal antibodies in follicular lymphoma.

Lawrence E. Feldman, MD

Latest:

Dr. Feldman on Lenvatinib and Pembrolizumab Plus Chemotherapy in NSCLC

Lawrence E. Feldman, MD, discusses the phase 3 LEAP-006 trial evaluating lenvatinib and pembrolizumab plus chemotherapy in non–small cell lung cancer.

Lawrence Fong, MD

Latest:

Dr. Lawrence Fong on Managing the Side Effects of Immunotherapies

Lawrence Fong, MD, Professor, Department of Medicine (Hematology/Oncology), University of California San Francisco, discusses the importance of educating oncologists on the side effects of immunotherapies.

Lawrence H. Einhorn, MD

Latest:

Dr. Einhorn on Improving the Cure Rate and the Burden of Cure in Prostate Cancer

Lawrence H. Einhorn, MD, distinguished professor of medicine, division of hematology/oncology, Indiana University School of Medicine, Giant of Cancer Care: Genitourinary Cancer, discusses new methods being explored to help improve the cure rate in prostate cancer.

Lawrence I. Karsh, MD

Latest:

Hereditary Prostate Cancer—What Urologists Should Know

Historically, urologists have been the primary caretakers for men with localized prostate cancer, which is the most prevalent solid tumor in men over 50 years of age and the second-leading cause of cancer-specific mortality in the United States today.

Lawrence I. Karsh, MD, Urology Center of Colorado

Lawrence J. Schneiderman, MD

Latest:

Dr. Schneiderman on Rationing Medical Care

Lawrence J. Schneiderman, MD, professor emeritus, Medicine/Family & Preventive Medicine, University of California, San Diego (UCSD), discusses preparing doctors for the fact that medical care will have to be rationed in the future.

Lawrence J. Solin, MD

Latest:

Dr. Solin on Personalizing Treatment With the DCIS Score

Dr. Lawrence Solin from Einstein Medical Center on Personalizing Treatment With the DCIS Score

Lawrence Karsh, MD

Latest:

Dr. Karsh on the TERRAIN Trial for Prostate Cancer

Lawrence Karsh, MD, FACS, director, Clinical Research Department, The Urology Center of Colorado, discusses the TERRAIN trial, which compared enzalutamide with bicalutamide for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC).

Lawrence Mayer, PhD,

Latest:

Dr. Lawrence Mayer on CPX-351 for Acute Myeloid Leukemia

Lawrence Mayer, PhD, president, founder and chief scientific officer of Celator Pharmaceuticals, explains the technology behind CPX-351, a liposomal formulation of cytarabine and daunorubicin. CPX-351 was recently granted Fast Track Designation by the FDA for the treatment of elderly patients with relapsed acute myeloid leukemia (AML).

Lawrence N. Shulman, MD

Latest:

Dr. Shulman on Chemotherapy in Adjuvant Breast Cancer

Lawrence N. Shulman, MD, chief of staff, senior vice president for medical affairs, director, Center for Global Cancer Medicine, director, Department of Regional Strategy and Development, chief, Division of General Oncology, Dana-Farber Cancer Institute, discusses chemotherapy choices for patients with adjuvant breast cancer.

Lazaros John Lekakis, MD

Latest:

Dr. Lekakis on Managing the Toxicity of CAR T-Cell Therapy

Lazaros John Lekakis, MD, associate professor of clinical medicine, Sylvester Comprehensive Cancer Center, University of Miami, discusses managing the toxicity of CAR T-cell therapy.

Leah H. Biller, MD

Latest:

Dana-Farber Tackles Rising Incidence of Young-Onset Colorectal Cancer

Dana-Farber Cancer Institute launched the Young-Onset Colorectal Cancer Center, among the first of its kind, in March 2019 to provide expert and compassionate clinical care, promote scientific discovery and innovation to elucidate underlying biological mechanisms, identify risk factors, and facilitate development of novel therapies, and improve prevention and early detection by raising public awareness of the rising burden of CRC in young adults.

Lecia Sequist, MD, MPH

Latest:

Dr. Sequist on the Importance of Broad Molecular Testing in Lung Cancer

Lecia V. Sequist, MD, MPH, discusses the importance of implementing broad molecular testing in lung cancer.

Lecia V. Sequist, MD

Latest:

Dr. Sequist Discusses Combination Regimens in EGFR+ NSCLC

Lecia V. Sequist, MD, associate professor of medicine, Harvard Medical School, Mary B. Saltonstall Chair, Oncology, Massachusetts General Hospital Center, discusses combination regimens for patients with EGFR-positive non-small cell lung cancer (NCSLC).

Lecia V. Sequist, MD, MPH

Latest:

Dr. Sequist on Pembrolizumab Monotherapy in Nonsquamous NSCLC

Lecia V. Sequist, MD, MPH, the Landry Family Associate Professor of Medicine at Harvard Medical School, and director, Center for Innovation in Early Cancer Detection, Massachusetts General Hospital, discusses the use of pembrolizumab (Keytruda) monotherapy versus the combination of pembrolizumab and chemotherapy in advanced nonsquamous non–small cell lung cancer (NSCLC).

Lecia V. Sequist, MD, MPH, Harvard